Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C13H13N3O3
CAS Number:
Molecular Weight:
259.26
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Product Name
Lenalidomide, ≥98% (HPLC)
ligand
lenalidomide
assay
≥98% (HPLC)
form
powder
reaction suitability
reagent type: ligand
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C1N(C2CCC(NC2=O)=O)CC3=C1C=CC=C3N
InChI
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChI key
GOTYRUGSSMKFNF-UHFFFAOYSA-N
Biochem/physiol Actions
Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent that is approved drug for treatment of multiple myeloma. Apparently Lenalidomide is a ligand of ubiquitin E3 ligase cereblon that induces the enzyme to degrade the Ikaros transcription factors IKAROS family zinc finger 1 (IKZF1) and IKZF3. Lenalidomide possess pleiotropic antitumor effects. It is used in the treatment of 5q-deletion associated myelodysplastic syndrome (del(5q)-MDS).
Still not finding the right product?
Explore all of our products under Lenalidomide
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B - STOT RE 2
target_organs
Blood
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuan Xiao Zhu et al.
Blood, 118(18), 4771-4779 (2011-08-24)
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of
Georg Petzold et al.
Nature, 532(7597), 127-130 (2016-02-26)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
Donovan KA, et al.
eLife, 7, e38430-e38430 (2018)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2283-100MG | 04061835307111 |
| SML2283-250MG | 04061835307128 |
